Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CHD
MCID: CRN300
MIFTS: 63

Coronary Heart Disease 1 (CHD)

Categories: Blood diseases, Genetic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Coronary Heart Disease 1

About this section

MalaCards integrated aliases for Coronary Heart Disease 1:

Name: Coronary Heart Disease 1 56 29 37
Coronary Heart Disease 56 74 29 54 6 62 17 71
Coronary Heart Disease, Susceptibility to, 1 56 71
Coronary Heart Disease, Susceptibility to 56 13
Heart, Coronary, Disease, Susceptibility to, Type 1 39
Coronary Arteriosclerosis 71
Coronary Artery Disease 71
Chds1 56
Chd 47

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 56 607339
UMLS 71 C0010054 C0010068 C1846418 more
Sources

Summaries for Coronary Heart Disease 1

About this section
PubMed Health : 62 About coronary heart disease: Coronary heart disease (CHD) is a disease in which a waxy substance called plaque (plak) builds up inside the coronary arteries. These arteries supply oxygen-rich blood to your heart muscle. When plaque builds up in the arteries, the condition is called atherosclerosis (ATH-er-o-skler-O-sis). The buildup of plaque occurs over many years.

MalaCards based summary : Coronary Heart Disease 1, also known as coronary heart disease, is related to myocardial infarction and diabetes mellitus, noninsulin-dependent, and has symptoms including edema, tremor and chest pain. An important gene associated with Coronary Heart Disease 1 is APOC3 (Apolipoprotein C3), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Sulfasalazine and Hydromorphone have been mentioned in the context of this disorder. Affiliated tissues include Limb and Bone.

Wikipedia : 74 Coronary artery disease (CAD), also known as coronary heart disease (CHD) or ischemic heart disease... more...

More information from OMIM: 607339
Sources

Related Diseases for Coronary Heart Disease 1

About this section

Diseases in the Coronary Heart Disease 1 family:

Coronary Heart Disease 3 Coronary Heart Disease 2
Coronary Heart Disease 4 Coronary Heart Disease 5
Coronary Heart Disease 7 Coronary Heart Disease 8
Coronary Heart Disease 9 Coronary Heart Disease 6

Diseases related to Coronary Heart Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 740)
# Related Disease Score Top Affiliating Genes
1 myocardial infarction 32.0 MIR208A MIR17 MIR155 MIR126 CDKN2B-AS1 CDKN2B
2 diabetes mellitus, noninsulin-dependent 31.8 WFDC21P SOCS1 MIR17 MIR140 MIR126 GAS5
3 diabetes mellitus 31.8 SOCS1 MIR17 MIR155 MIR145 MIR140 MIR126
4 body mass index quantitative trait locus 11 31.7 SOCS1 MIR17 MIR155 MIR140 MIR126 H19
5 cardiovascular system disease 31.7 MIR17 MIR155 MIR145 MIR126 CDKN2B-AS1 APOC3
6 hypertension, essential 31.7 MIR92B MIR208A MIR17 MIR155 MIR145 MIR126
7 non-alcoholic fatty liver disease 31.6 MIR17 MIR155 MIR140 MIR126 APOC3
8 arteries, anomalies of 31.5 MIR17 MIR155 MIR145 MIR140 MIR126
9 ovarian disease 30.9 MIR182 MIR17 MIR145 MIR140 MIR126
10 aortic disease 30.9 MIR17 MIR145 MIR126
11 heart disease 30.8 MIR208A MIR17 MIR155 MIR145 MIR126 H19
12 connective tissue disease 30.8 MIR17 MIR155 MIR145 MIR140 MIR126
13 b-cell lymphoma 30.7 SOCS1 MIR17 MIR155 GAS5 CDKN2B CDKN2A
14 inherited metabolic disorder 30.6 MIR17 MIR155 MIR126 APOC3
15 gastric cancer 30.6 MIR17 MIR155 MIR145 MIR140 MIR126 HOTTIP
16 endometriosis 30.5 MIR145 MIR126 H19 CDKN2B-AS1
17 prostate cancer 30.5 SOCS1 MIR182 MIR17 MIR145 MIR126 IGF2-AS
18 cervical cancer 30.4 MIR17 MIR155 MIR145 MIR140 MIR126 H19
19 gallbladder disease 30.4 MIR17 MIR145 MIR126
20 prostate disease 30.4 MIR182 MIR17 MIR145 MIR140 MIR126 IGF2-AS
21 bladder cancer 30.4 MIR182 MIR17 MIR145 MIR126 H19 GAS5
22 esophageal cancer 30.3 MIR155 MIR145 MIR140 MIR126 HOTTIP H19
23 lung cancer 30.3 MIR92B MIR182 MIR17 MIR155 MIR145 MIR140
24 colorectal cancer 30.3 SOCS1 MIR182 MIR17 MIR155 MIR145 MIR140
25 ovarian cancer 30.2 MIR182 MIR17 MIR155 MIR145 MIR140 MIR126
26 hepatocellular carcinoma 30.1 SOCS1 MIR182 MIR17 MIR155 MIR145 MIR140
27 hyperlipoproteinemia, type iii 12.1
28 coronary heart disease 8 12.0
29 angina pectoris 11.8
30 lipoprotein quantitative trait locus 11.7
31 coronary heart disease 2 11.7
32 coronary heart disease 4 11.7
33 coronary heart disease 5 11.7
34 hypercholesterolemia, familial, 1 11.7
35 hyperlipidemia, familial combined, 3 11.7
36 coronary heart disease 3 11.6
37 coronary heart disease 7 11.6
38 coronary heart disease 9 11.6
39 coronary heart disease 6 11.6
40 familial hypercholesterolemia 11.6
41 cardiac arrest 11.6
42 abdominal obesity-metabolic syndrome 1 11.5
43 alopecia, androgenetic, 1 11.5
44 hypoalphalipoproteinemia, primary, 1 11.5
45 hyperlipidemia, familial combined, 1 11.5
46 cleft palate, cardiac defect, genital anomalies, and ectrodactyly 11.4
47 high density lipoprotein cholesterol level quantitative trait locus 1 11.3
48 total anomalous pulmonary venous return 1 11.3
49 8p23.1 duplication syndrome 11.2
50 lipid metabolism disorder 11.0

Graphical network of the top 20 diseases related to Coronary Heart Disease 1:



Diseases related to Coronary Heart Disease 1
Sources

Symptoms & Phenotypes for Coronary Heart Disease 1

About this section

Clinical features from OMIM:

607339

UMLS symptoms related to Coronary Heart Disease 1:


edema, tremor, chest pain, angina pectoris, equilibration disorder, substernal pain
Sources

Drugs & Therapeutics for Coronary Heart Disease 1

About this section

PubMed Health treatment related to Coronary Heart Disease 1: 62

Treatments for coronary heart disease (CHD) include lifestyle changes, medicines, and medical procedures. Treatment goals may include: Relieving symptoms. Reducing risk factors in an effort to slow, stop, or reverse the buildup of plaque . Lowering the risk of blood clots forming. (Blood clots can cause a heart attack .) Widening or bypassing clogged arteries . Preventing complications of CHD.

Drugs for Coronary Heart Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 881)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
2
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
3
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
4
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
5
Chlorthalidone Approved Phase 4 77-36-1 2732
6
Fenoldopam Approved Phase 4 67227-57-0, 67227-56-9 3341
7
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
8
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
10
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
11
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
12
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
13 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
14
Eplerenone Approved Phase 4 107724-20-9 150310 443872
15
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
16
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
17
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
18
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
19
Probucol Approved, Investigational Phase 4 23288-49-5 4912
20
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
21
Digoxin Approved Phase 4 20830-75-5 30322 2724385
22
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
23
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
24
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
25
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
26
Zinc Approved, Investigational Phase 4 7440-66-6 32051
27
Cosyntropin Approved Phase 4 16960-16-0 16129617
28
Etomidate Approved Phase 4 33125-97-2 36339 667484
29
Histamine Approved, Investigational Phase 4 51-45-6 774
30
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
31
Polyestradiol phosphate Approved Phase 4 28014-46-2
32
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
33
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
34
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
35
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
36
Famotidine Approved Phase 4 76824-35-6 3325
37
Norepinephrine Approved Phase 4 51-41-2 439260
38
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
39
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
40
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
41
Ticlopidine Approved Phase 4 55142-85-3 5472
42
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
43
Remifentanil Approved Phase 4 132875-61-7 60815
44
Vorapaxar Approved Phase 4 618385-01-6
45
Saxagliptin Approved Phase 4 361442-04-8 11243969
46
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
47
Magnesium citrate Approved Phase 4 3344-18-1
48
Citalopram Approved Phase 4 59729-33-8 2771
49
Nifedipine Approved Phase 4 21829-25-4 4485
50
Nevirapine Approved Phase 4 129618-40-2 4463

Interventional clinical trials:

(show top 50) (show all 6330)
# Name Status NCT ID Phase Drugs
1 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
2 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
3 Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography. Unknown status NCT02874287 Phase 4 Hydroxychloroquine Sulfate Tablets;Placebo Tablets
4 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
5 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
6 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
7 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
8 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
9 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
10 RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT Unknown status NCT01230723 Phase 4
11 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
12 Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
13 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
14 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
15 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
16 Prospective, Randomized Trial of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coatings Unknown status NCT01068106 Phase 4
17 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
18 Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up. Unknown status NCT00888758 Phase 4
19 Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
20 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
21 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
22 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
23 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
24 Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
25 Comparison of Efficacy and Safety of Ivabradine Versus Metoprolol for Controlling Heart Rate Prior to 640-Slice Computed Tomographic Angiography in Elective Patients Unknown status NCT01755663 Phase 4 Ivabradine and Metoprolol
26 Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study Unknown status NCT02154295 Phase 4
27 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
28 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
29 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
30 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
31 The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients Unknown status NCT02011906 Phase 4
32 Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled Trial Unknown status NCT01810224 Phase 4
33 Epicardial Fat Evaluation to Predict Clinical Outcomes in Patients Affected by Coronary Artery Disease and Treated by Coronary Artery Bypass Grafting: Diabetic vs. Non Diabetic Patients, and Incretin Therapy Effect; The EPI.FAT.IN Study Unknown status NCT03360981 Phase 4 Incretins
34 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
35 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
36 Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol) Unknown status NCT03277079 Phase 4 statin + ezetimibe;statin + ezetimibe + Nutraceuticals
37 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
38 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
39 Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting: A Double-blind, Placebo-controlled, Randomized Trial Unknown status NCT03049085 Phase 4 Aspirin;vitamin C
40 Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease Unknown status NCT01446094 Phase 4 regadenoson
41 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
42 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
43 Studies of Application of Combined General Anesthesia and Bilateral Thoracic Paravertebral Block by Ropivacaine in Patients Undergoing Off-pump Coronary Artery Bridge Graft - a Random Double Blind Controlled Study Unknown status NCT02727712 Phase 4 Anesthesia drugs during the surgery
44 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
45 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
46 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
47 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
48 Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 Unknown status NCT00262574 Phase 4 Nesiritide,
49 Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms. Unknown status NCT01776567 Phase 4
50 Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine

Search NIH Clinical Center for Coronary Heart Disease 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


atorvastatin
Atorvastatin calcium
cerivastatin
Cerivastatin sodium
Cholestyramine Resin
Clofibrate
colesevelam
Colesevelam hydrochloride
Colestipol
Colestipol Hydrochloride
Dextrothyroxine
Dextrothyroxine Sodium
eptifibatide
Fenofibrate
Fish Liver Oils
fluvastatin
Fluvastatin sodium
Gemfibrozil
Isosorbide
Isosorbide Dinitrate
Isosorbide Mononitrate
Lovastatin
Pravastatin
Pravastatin Sodium
Probucol
rosuvastatin
Simvastatin
Sulfinpyrazone
tirofiban
TIROFIBAN HYDROCHLORIDE

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Coronary Heart Disease 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Coronary Heart Disease 1:
ACT34-CMI, bone marrow-derived cells for ischemic heart diseases
Adipocell, adipose-derived stem cells for chronic ischemic cardiomyopathy
Adipose-derived mesenchymal stromal stem cells for ischemic heart disease
ADRCs, adipose-derived regenerative cells for cardiovascular disease
ALD-201, bone marrow-derived cells for coronary artery disease
AMDC, autologous muscle-derived cells for ischemic heart failure
Autologous bone marrow-derived mesenchymal stem cells for treatment of heart muscle damage
Bone marrow-derived CD133+ stem cells for treatment of ischemic heart disease
Bone marrow-derived mesenchymal stem cells for treatment of heart diseases
Bone marrow-derived mesenchymal stem cells for treatment of ischemic cardiomyopathy
Bone marrow-derived mesenchymal stem cells for treatment of ischemic cardiomyopathy during artery bypass grafting
Bone marrow-derived mesenchymal stem cells for treatment of ischemic heart disease
Bone marrow-derived mononuclear cells for ischemic cardiomyopathy
Bone marrow-derived mononucleated cells for heart disease
Bone marrow-derived stem cells for treatment of chronic ischemic heart failure
Bone marrow-derived stem cells for treatment of ischemic cardiomyopathy
Bone marrow-derived stem cells for treatment of severe chronic ischemic heart disease
Cardiac stem cells for treatment of ischemic cardiomyopathy
Cardiocell, bone marrow-derived mesenchymal stem cells for heart diseases
Combination therapy of mononuclear cells with laser for coronary disease
Embryonic stem cell-derived cardiomyocytes for ischemic myocardium
Enriched bone marrow-derived progenitor cells for heart diseases
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Mesendo, stem cell combination for treatment of cardiovascular diseases
Peripheral mononuclear cells CD34+ stem cells for treatment of myocardial ischemia
Peripheral or bone marrow-derived stem cells for chronic heart failure
StempeucelICM, mesenchymal stem cells for ischemic cardiomyopathy
Embryonic/Adult Cultured Cells Related to Coronary Heart Disease 1:
Bone marrow-derived CD34+ stem cells (ACT34) PMIDs: 22163120 9020076 17562958 20448213 12551872 11283669 21737787
VEGF-A165-stimulated ADSCs
Adipose-derived stem and regenerative cells PMIDs: 22281257 21082397
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 19627297 10430905
Autologous muscle-derived cells
Bone marrow-derived mesenchymal stem cells (family) PMIDs: 21052537 19591227
Bone marrow-derived CD133+ cells
Bone marrow-derived mesenchymal stem cells PMIDs: 22940024 21392602
Bone marrow-derived hematopoietic stem cells (family)
Bone marrow-derived stem cells
Bone marrow-derived mononuclear cells (family) PMIDs: 22940024 21392602
Porcine bone marrow-derived mesenchymal stem cells PMIDs: 22940024 21392602
Human cardiac stem cells PMIDs: 22088800 22965994
Cardiomyocyte-like cells PMIDs: 18941512
Bone marrow-derived progenitor cells PMIDs: 16990385 22651868 16990384 18794392 22936827 23362308
Bone marrow-derived mononuclear cells PMIDs: 21323410 20631864
Bone marrow-derived mesenchymal stem cells PMIDs: 21323410 20631864
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived mononuclear cells PMIDs: 20668107 19761394 22834565 21596713
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 18720444
Sources

Genetic Tests for Coronary Heart Disease 1

About this section

Genetic tests related to Coronary Heart Disease 1:

# Genetic test Affiliating Genes
1 Coronary Heart Disease 1 29 CX3CR1
2 Coronary Heart Disease 29
Sources

Anatomical Context for Coronary Heart Disease 1

About this section

MalaCards organs/tissues related to Coronary Heart Disease 1:

40
Heart, Endothelial, Testes, Bone, Kidney, Liver, Breast
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Coronary Heart Disease 1:
# Tissue Anatomical CompartmentCell Relevance
1 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
2 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
Sources

Publications for Coronary Heart Disease 1

About this section

Articles related to Coronary Heart Disease 1:

(show top 50) (show all 32465)
# Title Authors PMID Year
1
A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. 61 56
11734540 2001
2
Genetic variants in the KIF6 region and coronary event reduction from statin therapy. 56
20886236 2011
3
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. 56
20933357 2010
4
KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. 56
20854963 2010
5
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. 56
17554300 2007
6
Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease. 46
21195052 2011
7
Circulating microRNAs in patients with coronary artery disease. 46
20595655 2010
8
Gene expression profiling in whole blood of patients with coronary artery disease. 46
20528768 2010
9
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. 61 54
20479152 2010
10
Genetic and environmental determinants of total and high-molecular weight adiponectin in families with low HDL-cholesterol and early onset coronary heart disease. 54 61
20056223 2010
11
Effect of statin therapy on leptin levels in patients with coronary heart disease. 54 61
20338208 2010
12
Demographic and cardiovascular risk factors modify association of fasting insulin with incident coronary heart disease and ischemic stroke (from the Atherosclerosis Risk In Communities Study). 61 54
20451688 2010
13
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. 61 54
20452521 2010
14
Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population. 54 61
20207770 2010
15
Does interleukin-18 or tumour necrosis factor-alpha have an independent association with the risk of coronary heart disease? Results from a prospective study in New Zealand. 54 61
20096599 2010
16
Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease. 61 54
20379055 2010
17
Association between the interleukin-6 gene -572G/C and -597G/A polymorphisms and coronary heart disease in the Han Chinese. 61 54
20190679 2010
18
Leptin, adiponectin, their ratio and risk of Coronary Heart Disease: results from the MONICA/KORA Augsburg Study 1984-2002. 61 54
19732895 2010
19
Evaluation of serum levels of C-reactive protein and lipid profiles in patients with chronic periodontitis and/or coronary heart disease in an ethnic Han population. 54 61
20213025 2010
20
Serum adiponectin and resistin levels in major depressive disorder. 61 54
19694629 2010
21
Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease. 54 61
20339975 2010
22
Interrelationships of Factor VII activity and plasma leptin with insulin resistance in coronary heart disease. 61 54
19781705 2010
23
Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease. 54 61
19936703 2010
24
Higher level of systemic C-reactive protein is independently predictive of coronary heart disease in older community-dwelling adults: the three-city study. 54 61
20002508 2010
25
Association of LT-alpha Ala252Gly gene polymorphism and the genetic predisposition of coronary heart disease in Chinese. 61 54
19365711 2010
26
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. 61 54
20031199 2010
27
The common biological basis for common complex diseases: evidence from lipoprotein lipase gene. 54 61
19639021 2010
28
Influence of genetic polymorphisms of glutathione S-transferase T1 (GSTT1) and M1 (GSTM1) on hematological parameters. 54 61
19662515 2010
29
Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study. 54 61
19473179 2010
30
Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. 54 61
19669729 2009
31
Glucocorticoid receptor gene and depression in patients with coronary heart disease: the Heart and Soul Study-2009 Curt Richter Award Winner. 61 54
19783104 2009
32
Evaluating the causal relevance of diverse risk markers: horizontal systematic review. 61 54
19892791 2009
33
Plasma PLTP activity is inversely associated with HDL-C levels. 54 61
19948027 2009
34
Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study. 61 54
19922611 2009
35
Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease. 61 54
19863872 2009
36
Association of cystatin C with ischemia in patients with coronary heart disease. 61 54
19816865 2009
37
P-selectin gene polymorphisms and risk of coronary heart disease among Tunisians. 54 61
19082691 2009
38
Is polymorphism within eNOS gene associated with the late onset of myocardial infarction? A pilot study. 61 54
19505886 2009
39
[Effect of renshen jianxin capsule for alleviating insulin resistance in patients with coronary heart disease and glucose tolerance impairment]. 61 54
19960983 2009
40
Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. 54 61
19732605 2009
41
The transcription factor TFAP2B is associated with insulin resistance and adiposity in healthy adolescents. 61 54
19325541 2009
42
Hepatocyte growth factor plays a critical role in the regulation of cytokine production and induction of endothelial progenitor cell mobilization: a pilot gene therapy study in patients with coronary heart disease. 61 54
19215239 2009
43
APOE genotype, lipids, and coronary heart disease risk: a prospective population study. 61 54
19667307 2009
44
[Association between hemoglobin scavenger receptor CD163 expression and coronary atherosclerotic severity in patients with coronary heart disease]. 54 61
19961729 2009
45
The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. 61 54
19411665 2009
46
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. 54 61
19567438 2009
47
Expression of heat shock proteins and nitrotyrosine in small arteries from patients with coronary heart disease. 54 61
19626397 2009
48
Adiponectin and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study. 54 61
19111833 2009
49
Does a gene polymorphism predisposing to an intermediate phenotype predict the risk of disease? A lesson from CETP, high-density lipoprotein-cholesterol and coronary heart disease. 54 61
19465783 2009
50
Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. 54 61
20031597 2009